Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis – A Systematic Literature Review

References

• Stevens SRC. History of development of TNF inhibitors. In: Weinberg JM, editor. TNF-Alpha Inhibitors. Milestones in Drug Therapy. Basel: Birkhäuser; 2006;9–22.
   Google Scholar
• Todoerti M, Favalli EG, Iannone F, et al. Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. Rheumatology (Oxford). 2018;57(57 Suppl 7):vii42–vii53. doi:10.1093/rheumatology/key195
   PubMedGoogle Scholar
• NHS England. Commissioning framework for biological medicines (including biosimilar medicines). 2017.
   Google Scholar
• Liu Y, Yang M, Garg V, Wu EQ, Wang J, Skup M. Economic impact of non-medical switching from originator biologics to biosimilars: a systematic literature review. Adv Ther. 2019;36:1851–1877.
   PubMed Web of Science ®Google Scholar
• Cannon GW, DuVall SL, Haroldsen CL, et al. Clinical outcomes and biologic costs of switching between tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. Adv Ther. 2016;33(8):1347–1359. doi:10.1007/s12325-016-0371-0
   Web of Science ®Google Scholar
• Meissner B, Trivedi D, You M, Rosenblatt L. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. J Med Econ. 2014;17(4):259–265. doi:10.3111/13696998.2014.893241
   PubMedGoogle Scholar
• Rashid N, Lin AT, Aranda G, et al. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system. J Med Econ. 2016;19(6):568–575. doi:10.3111/13696998.2016.1142448
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol. 2002;29(8):1631–1638.
   PubMed Web of Science ®Google Scholar
• Fries JF. Effectiveness and toxicity considerations in outcome directed therapy in rheumatoid arthritis. J Rheumatol Suppl. 1996;44:102–106.
   Google Scholar
• Pincus T, Marcum SB, Callahan LF, et al. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: I. Nonsteroidal antiinflammatory drugs. J Rheumatol. 1992;19(12):1874–1884.
   Web of Science ®Google Scholar
• Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence. 2009;3:335–344. doi:10.2147/PPA
   PubMed Web of Science ®Google Scholar
• Zhang M, Brenneman SK, Carter CT, et al. Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis. Patient Prefer Adherence. 2015;9:777–784. doi:10.2147/PPA.S85773
   PubMed Web of Science ®Google Scholar
• Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching Reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463–478. doi:10.1007/s40265-018-0881-y
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097
   Google Scholar
• Wells G, Shea B, O’Connell D. Newcastle-ottawa quality assessment scale–cohort studies. 2012. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed June 15, 2019.
   Google Scholar
• Bolge SC, Goren A, Tandon N. Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective. Patient Prefer Adherence. 2015;9:121–131. doi:10.2147/PPA
   PubMed Web of Science ®Google Scholar
• De Keyser F, Hoffman I, Durez P, et al. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry. J Rheum. 2014;41(9):1761–1765. doi:10.3899/jrheum.131279
   PubMed Web of Science ®Google Scholar
• Glintborg B, Sorensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76(8):1426–1431. doi:10.1136/annrheumdis-2016-210742
   PubMed Web of Science ®Google Scholar
• Kadar G, Balazs E, Soos B, et al. Disease activity after the discontinuation of biological therapy in inflammatory rheumatic diseases. Clin Rheumatol. 2014;33(3):329–333. doi:10.1007/s10067-014-2508-3
   Web of Science ®Google Scholar
• Leon L, Rodriguez-Rodriguez L, Rosales Z, et al. Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice. Scand J Rheumatol. 2016;45(6):456–460. doi:10.3109/03009742.2016.1141979
   PubMed Web of Science ®Google Scholar
• Lorenzin M, Ortolan A, Frallonardo P, Oliviero F, Punzi L, Ramonda R. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord. 2015;16(1):166. doi:10.1186/s12891-015-0620-4
   PubMedGoogle Scholar
• Narula N, Peerani F, Meserve J, et al. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium. Am J Gastroenterol. 2018;113(9):1345–1354. doi:10.1038/s41395-018-0162-0
   PubMed Web of Science ®Google Scholar
• Neovius M, Arkema EV, Olsson H, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. 2015;74(2):354–360. doi:10.1136/annrheumdis-2013-204128
   PubMed Web of Science ®Google Scholar
• Oldroyd AGS, Symmons DPM, Sergeant JC, et al. Long-term persistence with rituximab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2018;57(6):1089–1096. doi:10.1093/rheumatology/key036
   Web of Science ®Google Scholar
• Rusman T, Ten Wolde S, Euser SM, et al. Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice. Int J Rheum Dis. 2018;21(4):836–842. doi:10.1111/1756-185X.13271
   Web of Science ®Google Scholar
• Scherlinger M, Germain V, Labadie C, et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Joint Bone Spine. 2018;85(5):561–567. doi:10.1016/j.jbspin.2017.10.003
   PubMed Web of Science ®Google Scholar
• Scherlinger M, Langlois E, Germain V, Schaeverbeke T. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4). Semin Arthritis Rheum. 2019;48(5):927–932. doi:10.1016/j.semarthrit.2018.07.005
   PubMed Web of Science ®Google Scholar
• Schmitz EMH, Benoy-de Keuster S, Meier AJL, et al. Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study. Clin Rheumatol. 2017;36(9):2129–2134. doi:10.1007/s10067-017-3686-6
   Web of Science ®Google Scholar
• Sepriano A, Ramiro S, van der Heijde D, et al. Effect of comedication with conventional synthetic disease-modifying antirheumatic drugs on retention of tumor necrosis factor inhibitors in patients with spondyloarthritis: a prospective cohort study. Arthritis Rheuma. 2016;68(11):2671–2679. doi:10.1002/art.39772
   Web of Science ®Google Scholar
• Thomas K, Flouri I, Repa A, et al. High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients. Clin Exp Rheumatol. 2018;36(2):254–262.
   Web of Science ®Google Scholar
• Tweehuysen L, Huiskes VJB, van den Bemt BJF, et al. Open-label, non-mandatory transitioning from originator etanercept to biosimilar SB4: six-month results from a controlled cohort study. Arthritis Rheuma. 2018;70(9):1408–1418. doi:10.1002/art.40516
   PubMed Web of Science ®Google Scholar
• Tweehuysen L, van den Bemt BJF, van Ingen IL, et al. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheuma. 2018;70(1):60–68. doi:10.1002/art.40324
   PubMed Web of Science ®Google Scholar
• Varela H, Villamanan E, Plasencia C, et al. Safety of antitumour necrosis factor treatments in chronic rheumatic diseases: therapy discontinuations related to side effects. J Clin Pharm Ther. 2016;41(3):306–309. doi:10.1111/jcpt.12393
   Web of Science ®Google Scholar
• Al Tabaa O, Etcheto A, Miceli-Richard C, Anna M, Dougados M Switch from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: the experience of Cochin University Hospital Paris-France. Paper presented at: Annual European Congress of Rheumatology, EULAR2018, Amsterdam.
   Google Scholar
• Alkoky H, Pakozdi A, Tahir H. Benepali switches in clinical practice - a positive single centre experience. Arthritis Rheuma. 2018;70(Supplement 9):2788–2789.
   Google Scholar
• Attipoe L, Patel S, Birt R, Crooks J, Hunt K, Grigoriou A. What factors predict good patient experiences of switching from reference etanercept to an etanercept biosimilar in a south west london general hospital? Rheumatology. 2018;57(Supplement 3):iii63.
   Google Scholar
• Baganz L, Meissner Y, Herzer P, et al. Treatment continuation on the etanercept original in comparison with a biosimilar. Arthritis Rheuma. 2018;70(Supplement 9):2789–2790.
   Google Scholar
• Bressler B, Greenup AJ, Bassel M, et al. Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn’s disease patients (EVOLVE) in Canada: interim results. J Crohn’s Colitis. 2018;12(Supplement 1):S382. doi:10.1093/ecco-jcc/jjx180.673
   Google Scholar
• Choquette D, Bessette L, Alemao E, et al. Retention rates of TNF inhibitors and abatacept used as a first biologic DMARD in the treatment of rheumatoid arthritis: 8 years of experience from the Rhumadata registry. J Rheum. 2018;45(7):1053.
   Web of Science ®Google Scholar
• Choquette D, Bessette L, Haraoui B, et al. Rituximab shows better sustainability than TNF inhibitors when used following initial biologic DMARD failure in the treatment of rheumatoid arthritis: 8 years of real-world observations from the RHUMADATA clinical database and registry. Ann Rheum Dis. 2017;76(Supplement 2):845–846.
   Google Scholar
• Conesa Mateos A, Fernandez-Prada M, Exposito-Molinero R, et al. Certolizumab Pegol’s effectiveness, retention rate and safety in psoriatic arthritis. Routine clinical practice data. Ann Rheum Dis. 2018;77(Supplement 2):1579.
   Google Scholar
• Curtis JR, Sullivan E, Kershaw J, Blackburn S, Mahajan P, Boklage S. Physician-reported behaviours and treatment trends of tumour necrosis factor inhibitor use: cycling versus switching in five European countries: france, Germany, Italy, Spain and the UK. Ann Rheum Dis. 2018;77(Supplement 2):1385–1386.
   Google Scholar
• De Cock D, Dyball S, Kearsley-Fleet L, Watson K, Hyrich K Profiling rheumatoid arthritis biosimilar switchers: data from the British society for rheumatology biologics register for rheumatoid arthritis. Paper presented at: Annual Conference of the British Society for Rheumatology 2018, Liverpool.
   Google Scholar
• De Cock D, Watson K, Hyrich KL. Biosimilars in the UK: early real world data from the british society for rheumatology biologics registers for rheumatoid arthritis. Ann Rheum Dis. 2017;76(Supplement 2):555–556.
   Google Scholar
• Dyball S, Hoskins V, Christy-Kilner S, Haque S. Effectiveness and tolerability of benepali in rheumatoid arthritis patients switched from enbrel. Arthritis Rheum Conf. 2017;69(Supplement):10.
   Google Scholar
• Exposito-Molinero R, Garcia-Portales R, Lamua-Riazuelo JR, et al. Effectiveness and retention rate of certolizumab pegol in spondyloarthritis. Real life data. Ann Rheum Dis. 2018;77(Supplement 2):1550.
   Google Scholar
• Favalli EG, Selmi C, Becciolini A, et al. The 8-year retention rate of the first TNF-inhibitor in the treatment of spondyloarthropathies: real-life data from a multicentric local registries. Ann Rheum Dis. 2016;75(Supplement 2):810. doi:10.1136/annrheumdis-2016-eular.3404
   Google Scholar
• Forejtova S, Zavada J, Szczukova L, Jarosova K, Philipp T, Pavelka K. A non-medical switch from originator infliximab to biosimilar CT-p13 in 36 patients with ankylosing spondylitis: 6-months clinical outcomes from the Czech Biologic registry attra. Arthritis Rheum Conf. 2017;69(Supplement 10).
   Google Scholar
• Glintborg B, Omerovic E, Danebod K, et al. One-year clinical outcomes in 1623 patients with inflammatory arthritis who switched from originator to biosimilar etanercept-an observational study from the Danish Danbio registry. Arthritis Rheum Conf. 2017;69(Supplement 10):1550.
   Google Scholar
• Glintborg B, Sorensen IJ, Omerovic E, et al. One-year follow-up of a nationwide cohort of patients with inflammatory arthritis, who switched from originator to biosimilar etanercept, focusing on patients who switched back to originator. An observational Danbio study. Ann Rheum Dis. 2018;77(Supplement 2):595–596.
   Google Scholar
• Gonzalez Fernandez CM, Alegre-Sancho JJ, Garcia-Carazo S, et al. Persistence on golimumab as second line biological therapy in patients with spondyloarthritis (axial spondyloarthritis and psoriatic arthritis). Go-beyond, a retrospective study. Ann Rheum Dis. 2018;77(Supplement 2):1543.
   Google Scholar
• Gonzalez Munoza C, Mesonero F, Bargallo A, et al. Efficacy and safety of vedolizumab in inflammatory bowel disease: real-life experience. J Crohn’s Colitis. 2018;12(Supplement 1):S486. doi:10.1093/ecco-jcc/jjx180.867
   Google Scholar
• Hacioglu A, Hatemi G, Esatoglu SN, et al. Tapering TNF inhibitors in rheumatoid arthritis: A retrospective study. Ann Rheum Dis. 2017;76(Supplement 2):1186.
   Google Scholar
• Haugeberg G, Bakland G, Rodevand E, Fevang BT, Diamantopoulos A, Hansen IJW. Drug survival and reason for drop-out in rheumatoid arthritis patients with a nonmedical switch from originator to biosimilar etanercept-preliminary data from a Norwegian multicenter study. Ann Rheum Dis. 2018;77(Supplement 2):1383.
   Google Scholar
• Hendricks O, Horslev-Petersen K. When etanercept switch fails - clinical considerations. Arthritis Rheum Conf. 2017;69(Supplement 10).
   Google Scholar
• Holroyd C, Wallis D, Bennett S, Clayton P, Edwards CJ. Switching from bio-original etanercept to biosimilar etanercept SB4: patient acceptability and outcomes in the real world. Ann Rheum Dis. 2017;76(Supplement 2):1180.
   Google Scholar
• Hoque T, Suddle A, Herdman L, Kitchen J. Patient perceptions of switching to biosimilars. Rheumatology. 2018;57(Supplement 3):iii67–iii68.
   Google Scholar
• Karakoc Y, Ercan I. Drug survival analysis of tofacitinib in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77(Supplement 2):1411.
   Google Scholar
• Kellner H. High acceptance rate in RA, AS and PsA patients when being started on biosimilar TNF or being switched from the original TNF MAB (remicade, enbrel) - a single center experience. Ann Rheum Dis. 2017;76(Supplement 2):1436.
   Google Scholar
• Layegh Z, Ruwaard J, Hebing RC, et al. Efficacious transition from reference product infliximab to the biosimilar in daily practice. Ann Rheum Dis. 2018;77(Supplement 2):1733.
   Google Scholar
• Lee SY, Szeto MCH, Galloway JB. Bio-similar to bio-originator switchback: not a reliable quality indicator. Ann Rheum Dis. 2018;77(Supplement 2):1727–1728.
   Google Scholar
• Ma J, Petford S, Jones L, Douglas K, John H. Audit of the clinical efficacy and safety of etanercept biosimilar to its product in patients with inflammatory arthritis: experience from a district general hospital in The United Kingdom. Ann Rheum Dis. 2018;77(Supplement 2):1386.
   Google Scholar
• Madenidou A-V, Jeffries A, Varughese S, et al. Switching patients with arthritis from etanercept (enbrel) to the biosimilar drug, benepali: a single- center retrospective observational study. Paper presented at: American College of Rheumatology, ACR2018, Chicago.
   Google Scholar
• Mease P, Liu M, Gershenson B, Hur P, Greenberg J. Discontinuation and switching patterns of tumour necrosis factor inhibitor (TNFi) therapy in TNFi-naive and TNFi-experienced patients with psoriatic arthritis in the US Corrona psoriatic arthritis/spondyloarthritis (PSA/SPA) registry. Ann Rheum Dis. 2018;77(Supplement 2):382.
   Google Scholar
• Mease PJ, Van Der Heijde D, Karki C, Liu M, Park Y, Greenberg JD. Discontinuation of tumor necrosis factor inhibitor therapy in us patients with ankylosing spondylitis: data from the corrona psoriatic arthritis/spondyloarthritis (PSA/SPA) registry. Arthritis Rheum Conf. 2017;69(Supplement):10.
   Google Scholar
• Movahedi M, Hepworth E, Mirza R, Cesta A, Larche M, Bombardier C. Time to discontinuation of biologic therapy by mechanism of action in rheumatoid arthritis: results from a rheumatoid arthritis cohort. Arthritis Rheuma. 2018;70(Supplement 9):624–625.
   Google Scholar
• Muskens WD, Rongen-van Dartel SAA, Adang E, Van Riel PL. The influence of switching from etanercept originator to its biosimilar on effectiveness and and the impact of shared decision making on retention and withdrawal rates. Ann Rheum Dis. 2018;77(Supplement 2):1399.
   Google Scholar
• Nolkha N, Sheeran T, Venkatachalam S. Drug survival and efficacy of abatacept in rheumatoid arthritis patients in routine care - 7 year experience from a single centre in the United Kingdom. Ann Rheum Dis. 2018;77(Supplement 2):959–960.
   Google Scholar
• Orlandini B, Dragoni G, Bagnoli S, Deiana S, MacRi G, Rogai F. Prospective evaluation of clinical efficacy and safety of golimumab in biologic experienced and naive patients with moderate to severe ulcerative colitis: experience from a tertiary referral centre. J Crohn’s Colitis. 2017;11(Supplement 1):S284. doi:10.1093/ecco-jcc/jjx002.532
   Google Scholar
• Patel D, Ahmed TJ, Levy S, Rajak R, Sathananthan R, Horwood N. Analysis of rheumatoid arthritis patients who failed the switch from originator etanercept to biosimilar etanercept in Croydon. Rheumatology. 2018;57(Supplement 3):iii199.
   Google Scholar
• Perez Albaladejo L, Notario Ferreira I, Anon Onate I, et al. Survival at 6 and 12 months of ustekinumab in patients with psoriatic arthritis in conditions of clinical practice. Ann Rheum Dis. 2018;77(Supplement 2):1591–1592.
   Google Scholar
• Ramos L, Hernandez Camba A, De La Barreda R, et al. Clinical outcome with biological therapy in ulcerative colitis: real-world clinical setting from a multi-centre observational study. J Crohn’s Colitis. 2018;12(Supplement 1):S504. doi:10.1093/ecco-jcc/jjx180.906
   Google Scholar
• Rolon Campuzano R, Coronel Ale AL, Cerda OL, et al. Patterns of change of a second biological DMARD in a cohort of rheumatoid arthritis patients. J Clin Rheum. 2018;24(3 Supplement 1):S4. doi:10.1097/RHU.0000000000000692
   Google Scholar
• Salmon JH, Letarouilly JG, Coquerelle P, et al. Therapeutic maintenance of abatacept in rheumatoid arthritis: results of the RIC-ABA study (517 patients). Ann Rheum Dis. 2018;77(Supplement 2):1385.
   Google Scholar
• Sari A, Armagan B, Kilic L, et al. Abatacept experience in biologic naive rheumatoid arthritis patients: HUR-BIO real life results. Ann Rheum Dis. 2017;76(Supplement 2):854–855.
   Google Scholar
• Sebastiani M, Manfredi A, Iannone F, et al. Early discontinuation of first line biological treatment with etanercept in patients with rheumatoid arthritis: results from the Italian Gisea registry. Ann Rheum Dis. 2018;77(Supplement 2):957.
   Google Scholar
• Shah K, Flora K, Penn H. Clinical outcomes of a multi-disciplinary switching programme to biosimilar etanercept for patients with rheumatoid arthritis. Rheumatology. 2018;57(Supplement 3):iii143–iii144.
   Google Scholar
• Trope S, Thibaud G, Alliot F, Formont D, Krouri S. Quality of life of rheumatoid arthritis patients treated with biologics. Arthritis Rheuma. 2018;70(Supplement 9):1723.
   Google Scholar
• Uslu S, Can G, Senel S, et al. The efficacy and drug survival of the biosimilar infliximab (CT–P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the turkbio Registry. Paper presented at: American College of Rheumatology, ACR2018, Chicago.
   Google Scholar
• Valido A, Silva-Dinis J, Saavedra MJ, Bernardo N, Fonseca JE. Efficacy and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single centre. Ann Rheum Dis. 2018;77(Supplement 2):1712–1713.
   Google Scholar
• Vieira-Sousa E, Eusébio M, Ávila-Ribeiro P, et al. Tumour necrosis factor inhibitors persistence in psoriatic arthritis patients. Paper presented at: Annual European Congress of Rheumatology, EULAR2018, Amsterdam.
   Google Scholar
• Viola A, Pugliese D, Renna S, et al. Outcome in ulcerative colitis after switch from subcutaneous anti-TNF to intravenous anti-TNF: A multicentre study. Paper presented at: Conference of European Crohn´s and Colitis Organisation 2018, Vienna.
   Google Scholar
• Xibille D, Carrillo S, Sicsik S, et al. Preferences in the use of biologic drugs and adverse events in patients with rheumatic disease from a national biologics registry in Mexico. Ann Rheum Dis. 2018;77(Supplement 2):1377.
   Google Scholar
• Zengin B, Inanc N, Akar S, et al. Similar efficacy of tofacitinib on disease activity in rheumatoid arthritis patients with and without previous biologicals; results from the turkbio registry. Ann Rheum Dis. 2018;77(Supplement 2):1401–1402.
   Google Scholar
• RADS. The Danish Regions, RADS, Guidelines for Use of Biosimilar Infliximab and Etanercept; 2016.
   Google Scholar